Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Zhonghui Biotech: Signs a Strategic Cooperation Agreement with Watson Biotech Hong Kong for Overseas Market Expansion of Subunit Influenza Vaccines
Zhonghui Biotech Announcement: The company has entered into a strategic cooperation agreement with Watson Biotech Hong Kong Limited regarding the overseas market expansion of subunit influenza vaccines. According to the strategic cooperation agreement, both parties will conduct in-depth collaboration on the registration, sales, and commercialization of the group’s R&D products in overseas markets. The core product for this overseas expansion is the group’s self-developed trivalent subunit influenza vaccine (Hui’er Kangxin 3). This product was approved for market launch in January 2026 and is China’s first and only trivalent subunit influenza vaccine suitable for the entire population aged 6 months and above.